Gilead Sciences (NASDAQ:GILD) PT Raised to $75.00 at Royal Bank of Canada

Gilead Sciences (NASDAQ:GILD) had its target price lifted by investment analysts at Royal Bank of Canada from $74.00 to $75.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target points to a potential downside of 11.05% from the company’s current price.

GILD has been the subject of several other reports. BMO Capital Markets increased their price target on Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $70.00 price objective on shares of Gilead Sciences in a research report on Monday, September 16th. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Robert W. Baird reaffirmed a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research report on Thursday, June 20th. Finally, Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price on the stock in a research note on Monday, July 8th. Twelve analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $82.12.

Gilead Sciences Price Performance

GILD traded up $0.15 during trading on Friday, hitting $84.32. The company’s stock had a trading volume of 754,873 shares, compared to its average volume of 7,204,268. The firm’s 50 day moving average price is $78.91 and its two-hundred day moving average price is $71.85. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences has a 12 month low of $62.07 and a 12 month high of $87.86. The stock has a market capitalization of $105.05 billion, a price-to-earnings ratio of 234.19, a price-to-earnings-growth ratio of 2.91 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The business had revenue of $6.95 billion during the quarter, compared to analysts’ expectations of $6.64 billion. Sell-side analysts forecast that Gilead Sciences will post 3.78 earnings per share for the current fiscal year.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 36,847 shares of company stock valued at $3,033,340. Corporate insiders own 0.16% of the company’s stock.

Institutional Trading of Gilead Sciences

A number of institutional investors have recently modified their holdings of GILD. J. W. Coons Advisors LLC increased its position in shares of Gilead Sciences by 2.8% during the fourth quarter. J. W. Coons Advisors LLC now owns 11,130 shares of the biopharmaceutical company’s stock valued at $902,000 after acquiring an additional 300 shares in the last quarter. Campbell & CO Investment Adviser LLC lifted its stake in shares of Gilead Sciences by 19.1% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 7,436 shares of the biopharmaceutical company’s stock valued at $602,000 after buying an additional 1,195 shares in the last quarter. 1832 Asset Management L.P. lifted its stake in shares of Gilead Sciences by 31.2% during the 4th quarter. 1832 Asset Management L.P. now owns 31,171 shares of the biopharmaceutical company’s stock valued at $2,525,000 after buying an additional 7,411 shares in the last quarter. Exencial Wealth Advisors LLC increased its holdings in Gilead Sciences by 86.1% in the 4th quarter. Exencial Wealth Advisors LLC now owns 5,288 shares of the biopharmaceutical company’s stock valued at $428,000 after acquiring an additional 2,446 shares during the last quarter. Finally, Morningstar Investment Services LLC increased its holdings in Gilead Sciences by 124.9% in the 4th quarter. Morningstar Investment Services LLC now owns 15,191 shares of the biopharmaceutical company’s stock valued at $1,233,000 after acquiring an additional 8,437 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.